SynthesisScientific reports2026
Predictive value of serum biomarkers for survival in melanoma: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant melanoma is responsible for most skin cancer-related deaths due to its unpredictable behavior. Serum biomarkers have been widely investigated to improve prognostic assessment, yet their clinical utility remains inconclusive. This systematic review and meta-analysis evaluated the prognostic significance of serum biomarkers in melanoma. Following PRISMA guidelines and a registered protocol (PROSPERO: CRD42023486532), PubMed, EMBASE, and CENTRAL were searched for studies assessing biomarkers and survival outcomes. Univariate analyses revealed that elevated levels of LDH (HR 2.29, 95%-CI:1.97-2.67), S100B (HR 2.52, 95%-CI:1.59-3.99), circulating tumor DNA (ctDNA) (HR 2.61, 95%-CI:1.90-3.58), neutrophil-to-lymphocyte ratio (NLR) (HR 2.34, 95%-CI:1.86-2.93), and interleukin-6 (HR 3.11, 95%-CI:2.44-3.96) were significantly associated with reduced overall survival. Similarly, higher levels of LDH (HR 2.04, 95%-CI:1.68-2.47), S100B (HR 1.94, 95%-CI:1.39-2.70), ctDNA (HR 2.57, 95%-CI:1.95-3.39), and NLR (HR 2.38, 95%-CI:1.52-3.73) predicted shorter progression-free survival. These associations persisted in multivariable-adjusted analyses for LDH, ctDNA, NLR, IL-6, S100B, and CRP supporting their predictive relevance. LDH remains a reliable and cost-effective biomarker, while NLR may provide complementary prognostic information in patients receiving immune checkpoint inhibitors. Emerging biomarkers such as ctDNA demonstrate promising prognostic potential, but further evaluation is required before routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.